BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10823273)

  • 1. Vitronectin and substitution of a beta-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against alpha-helix F.
    Schousboe SL; Egelund R; Kirkegaard T; Preissner KT; Rodenburg KW; Andreasen PA
    Thromb Haemost; 2000 May; 83(5):742-51. PubMed ID: 10823273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop.
    Debrock S; Declerck PJ
    Thromb Haemost; 1998 Mar; 79(3):597-601. PubMed ID: 9531048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: implications for antibody-mediated PAI-1-neutralization and vitronectin-binding.
    Wind T; Jensen MA; Andreasen PA
    Eur J Biochem; 2001 Feb; 268(4):1095-106. PubMed ID: 11179976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solvent effects on activity and conformation of plasminogen activator inhibitor-1.
    Andreasen PA; Egelund R; Jensen S; Rodenburg KW
    Thromb Haemost; 1999 Mar; 81(3):407-14. PubMed ID: 10102470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redirection of the reaction between activated protein C and a serpin to the substrate pathway.
    Komissarov AA; Andreasen PA; Declerck PJ; Kamikubo Y; Zhou A; Gruber A
    Thromb Res; 2008; 122(3):397-404. PubMed ID: 18045665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases.
    Komissarov AA; Andreasen PA; Bødker JS; Declerck PJ; Anagli JY; Shore JD
    J Biol Chem; 2005 Jan; 280(2):1482-9. PubMed ID: 15516335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1.
    Bijnens AP; Ngo TH; Gils A; Dewaele J; Knockaert I; Stassen JM; Declerck PJ
    Thromb Haemost; 2001 May; 85(5):866-74. PubMed ID: 11372681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.
    Mathiasen L; Dupont DM; Christensen A; Blouse GE; Jensen JK; Gils A; Declerck PJ; Wind T; Andreasen PA
    Mol Pharmacol; 2008 Sep; 74(3):641-53. PubMed ID: 18559377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
    De Taeye B; Gils A; Vleugels N; Rabijns A; Declerck PJ
    Biochem Biophys Res Commun; 2004 Aug; 321(3):746-51. PubMed ID: 15358169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms.
    Hansen M; Busse MN; Andreasen PA
    Eur J Biochem; 2001 Dec; 268(23):6274-83. PubMed ID: 11733024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo.
    Van De Craen B; Scroyen I; Abdelnabi R; Brouwers E; Lijnen HR; Declerck PJ; Gils A
    Thromb Res; 2011 Jul; 128(1):68-76. PubMed ID: 21392818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
    Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
    J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
    Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
    Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I).
    Stoop AA; Jespers L; Lasters I; Eldering E; Pannekoek H
    J Mol Biol; 2000 Sep; 301(5):1135-47. PubMed ID: 10966811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
    Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
    Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of N-terminal residues in plasminogen activator inhibitor 1 on its antibody induced latency transition.
    Ngo TH; Zhou Y; Stassen JM; Declerck PJ
    Thromb Haemost; 2002 Aug; 88(2):288-93. PubMed ID: 12195702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering of conformations of plasminogen activator inhibitor-1. A crucial role of beta-strand 5A residues in the transition of active form to latent and substrate forms.
    Kirkegaard T; Jensen S; Schousboe SL; Petersen HH; Egelund R; Andreasen PA; Rodenburg KW
    Eur J Biochem; 1999 Jul; 263(2):577-86. PubMed ID: 10406969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1.
    Einholm AP; Pedersen KE; Wind T; Kulig P; Overgaard MT; Jensen JK; Bødker JS; Christensen A; Charlton P; Andreasen PA
    Biochem J; 2003 Aug; 373(Pt 3):723-32. PubMed ID: 12723974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A method for defining binding sites involved in protein-protein interactions: analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin.
    Royle G; Deng G; Seiffert D; Loskutoff DJ
    Anal Biochem; 2001 Sep; 296(2):245-53. PubMed ID: 11554720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1.
    Madsen JB; Dupont DM; Andersen TB; Nielsen AF; Sang L; Brix DM; Jensen JK; Broos T; Hendrickx ML; Christensen A; Kjems J; Andreasen PA
    Biochemistry; 2010 May; 49(19):4103-15. PubMed ID: 20387790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.